Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 8/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | UBE2N | P61088 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11262830 | 0.82 | AKR1B1 (0.47) | TP53MAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL14027398 | 0.80 | AKR1B1 (0.57) | IDO1LMNA | |
| SCHEMBL14027401 | 0.73 | MEN1 (0.44) | TP53MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL9421726 | 0.71 | FAAH (0.57) | KMT2AMEN1ALDH1A1IDO1 | |
| SCHEMBL4401170 | 0.70 | ALDH1A1 (0.62) | TP53KMT2AMEN1ALDH1A1IDO1 | |
| SCHEMBL15473438 | 0.70 | ALDH1A1 (0.53) | TP53MAPTSMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL3894959 | 0.69 | ALDH1A1 (0.53) | TP53KMT2AALDH1A1IDO1 | |
| SCHEMBL2377394 | 0.69 | ALDH1A1 (0.49) | KMT2AALDH1A1IDO1 | |
| SCHEMBL14027278 | 0.69 | MEN1 (0.56) | MAPTKMT2AMEN1RAB9ANPSR1 | |
| SCHEMBL13870208 | 0.68 | HPGD (0.50) | TP53MAPTSMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446120-B2 | Peptidomimetic modulators of cell adhesion | ADHEREX TECHNOLOGIES, INC. (CA) | 2008-11-04 | — | — | US | disclosed |
| US-20080260829-A1 | Bone morphogenic proteins (bmp); cell adhesion modulating agent; peptidomimetics of cyclic peptides comprising classical cadherin cell adhesion recognition (CAR) sequences; modulate cell adhesion and improve drug delivery | NEW YORK SOCIETY FOR THE RUPTURED AND CRIPPLED MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080081831-A1 | PEPTIDOMIMETIC MODULATORS OF CELL ADHESION | ADHEREX TECHNOLOGIES, INC. (CA) | 2008-04-03 | — | — | US | disclosed |
| US-7268115-B2 | Cyclic peptides; three-dimensional structures; screening; anticancer agents; angiogenesis inhibitors; drug delivery | ADHEREX TECHNOLOGIES, INC. (CA) | 2007-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080260829-A1 | Bone morphogenic proteins (bmp); cell adhesion modulating agent; peptidomimetics of cyclic peptides comprising classical cadherin cell adhesion recognition (CAR) sequences; modulate cell adhesion and improve drug delivery | BMP1, BMP2, BMP4 | TP53 1594/4885MAPT 1818/4885SMN1; SMN2 2848/4885 |
| US-20080081831-A1 | PEPTIDOMIMETIC MODULATORS OF CELL ADHESION | CDH1, EPCAM, VCAM1 | TP53 150/4885MAPT 3140/4885SMN1; SMN2 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.